Viking Therapeutics [VKTX] - Last Close: $38.48 Small-cap pharma firm Viking Therapeutics is also getting a boost after publishing positive data from a Phase 2 VENTURE Trial of VK2735. The experimental obesity drug reportedly achieved “significant” weight loss in a mid-stage study. Viking said the drug was found to be safe & well tolerated. It produced up to 13.1% placebo-adjusted mean weight loss, 14.7% from baseline, in 13 weeks f treatment with no plateau observed. VKTX is up 80.9% on roughly 4.5 million shares traded thus far. My Take: VKTX is taking advantage of the weight-loss drug hype generated by Ozempic. This was a mid-stage trial, so Phase 3 studies could provide another catalyst down the road. Janux Therapeutics [JANX] - Last Close: $15.10 Positive clinical data from two Phase 1a studies is giving this tiny biotech stock a major boost in today’s premarket. JANX007 and JANX008 produced positive results in clinical trials for metastatic prostate cancer and solid tumors, respectively. CEO David Campbell said the two drugs produced “encouraging safety and efficacy” data in the trials. JANX is one of this morning’s top stocks with a 122.0% gain, but volume is a bit light at slightly over 600K. My Take: JANX stock has been soaring for the past week, and this news just gave it another big boost. I anticipate we’ll see a pullback before the stock settles into a new trading range. Pubmatic [PUBM] - Last Close: $16.57 A strong after-market earnings release on Monday is fueling a big rally in shares of this micro-cap cloud infrastructure stock. Pubmatic posted stronger-than-expected earnings, revenues, and forward-looking guidance on its Q4 earnings report. The company also announced the launch of a $100 million share buyback plan that will run through the end of 2025. PUBM is up 29.3% on over 100K shares traded. My Take: PUBM was facing stiff resistance around $18, but this rally has already carried it well past that mark. It could find support at this level if the rally loses steam. Infobird [IFBD] - Last Close: $2.76 This tiny stock is rebounding from a steep loss on Monday, despite no news to explain the sudden reversal. Yesterday, Infobird pushed back a previously announced 1-for-8 reverse stock split scheduled for the same day until next week.
The news prompted a 26.9% loss for IFBD on Monday, but it’s dominating the premarket with a 135.0% gain on over 8.5 million shares traded.
My Take: IFBD’s recent upward trend appears to have significant momentum behind it, judging by the sudden reversal.
Gainers Advent Technologies [ADN] >> +19.9% SoundHound AI [SOUN] >> +22.6% TransMedics [TMDX] >> +14.8% Decliners Thoughtworks [TWKS] >> (29.2%) NRX Pharma [NRXP] >> (29.8%) Aaron’s [AAN] >> (22.6%) American Tower [AMT] ... AMSempra [SRE] ... AMConstellation Energy [CEG] ... AMAmerican Electric Power [AEP] ... AMRepublic Services [RSG] ... PMAgilent Technologies [A] ... PMExtra Space Storage [EXR] ... PMCoupang [CPNG] ... PMDevon Energy [DVN] ... PMSplunk [SPLK] ... PM Durable-goods orders [Jan] ... 8:30aS&P Case-Shiller home price index (20 cities) ... 9:00aConsumer confidence [Feb] ... 10:00a |